Home / Compare / Orforglipron vs Tirzepatide

Orforglipron vs Tirzepatide

Orforglipron vs Tirzepatide: how they work, doses used, FDA status and trial weight loss (about 12% vs 20.9%), with sources.

OrforglipronTirzepatide
Works onGLP-1 only (small molecule, not a peptide)GIP + GLP-1 (dual agonist)
How it is takenTablet, once daily (Foundayo)Injection, once weekly (Mounjaro, Zepbound)
US statusFDA-approved April 2026 (weight)FDA-approved (2022 diabetes, 2023 weight)
Highest dose17.2 mg daily (label)15 mg weekly (label)
Key trialATTAIN-1 (phase 3)SURMOUNT-1 (phase 3)
Average weight lossabout 12% at 72 weeks (highest dose)20.9% at 72 weeks (15 mg weekly)
Placebo in that trialabout 1-2%3.1%
Not a head-to-head comparison. The weight-loss numbers come from separate trials with different people, doses and lengths. A direct trial is the only way to know which works better.

How they differ

Orforglipron works on glp-1 only (small molecule, not a peptide); Tirzepatide works on gip + glp-1 (dual agonist). Orforglipron is taken as: tablet, once daily (foundayo).Tirzepatide is taken as: injection, once weekly (mounjaro, zepbound).

Dose schedules and warnings: Orforglipron dosage chart ยท Tirzepatide dosage chart.

Questions

Is orforglipron stronger than tirzepatide?
No trial has compared them directly. In separate trials, Orforglipron averaged about 12% weight loss (ATTAIN-1 (phase 3), 72 weeks) and Tirzepatide 20.9% (SURMOUNT-1 (phase 3), 72 weeks). Different trials enroll different people over different lengths of time, so the numbers are not a fair head-to-head comparison.
Is orforglipron FDA-approved?
FDA-approved April 2026 (weight).
Is tirzepatide FDA-approved?
FDA-approved (2022 diabetes, 2023 weight).

Sources

  1. Healio: FDA approves orforglipron, an oral GLP-1, for adults with obesity (Apr 2026)
  2. Jastreboff et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022

Last checked 2026-11-16. How we pick and check sources: methodology.